> Helicobacter pylori
and anaerobic bacterial
Helicobacter pylori infection is associated with gastritis, peptic ulcer and gastric cancer. There is a growing unmet medical need for an effective therapy for H. pylori eradication due to the rapid development of resistance to available antibiotics. TNP-2198 is a multi-targeting drug conjugate with a novel synergistic mode of action against H. pylori and anaerobic bacteria, including those that are resistant to current antibiotics. The compound has demonstrated a low propensity for development of resistance and potential for dramatically simplifying current therapy. TNP-2198 is currently under clinical development for the treatment of H. pylori and other anaerobic bacterial infections.